Under the partnership, the parties will also provide advanced data analysis and project management services.
ERG is a clinical research site firm focused on therapeutic areas such as psychiatry, Alzheimer’s disease, NASH, neurology, diabetes and more.
Invicro is a provider of imaging biomarkers, core lab services, and advanced analytics for clinical research.
This partnership will enable pharmaceutical sponsors to create a smooth inpatient and outpatient clinical research trials process.
The process is supported by centralised recruiting, operational excellence, project management support and clinical consultation.
Invicro chief commercial officer Roughan Sheedy said: “We are pleased to partner with such an industry leader in clinical research as ERG.
“We believe this alliance will allow our companies to jointly offer efficient and flexible clinical research studies that will deliver effective results to support our pharma sponsors’ drug development and clinical research projects.”
Until now, the ERG has completed around 5,000 clinical trials throughout the US, including both early and late-phase clinical trials under its advanced ERG portfolio.
Meanwhile, Invicro has processed nearly 25 million digital imaging and communications in medicine (DICOM) images. It also defined over six million unique quantification data points.
This combined expertise of ERG and Invicro will allow pharma and biotech customers to be decisive throughout clinical research trials and support more accurate and timely clinical trials.
ERG president and CEO Davide Molho said: “Invicro’s innovation and expertise in the area of medical imaging biomarkers, advanced analytics and software is unprecedented.
“We look forward to this collaboration to support the research community and their life-changing research projects across all therapeutic areas.”